Status:
COMPLETED
Host-pathogen Interactions During SARS-CoV-2 Infection
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Infection, Coronavirus
Severe Acute Respiratory Syndrome Coronavirus 2
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsib...
Eligibility Criteria
Inclusion
- Group E1:
- Age from birth to \<18 years old;
- Weight\> 3 kilogram (kg);
- Infection with SARS-CoV-2 virus confirmed by RT-PCR on upper respiratory tract sample
- No fever or respiratory symptoms;
- Not requiring hospitalization (or hospitalization not related to a SARS-CoV-2 infection);
- Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
- Beneficiary of a social security scheme
- Group E2:
- Age from birth to \<18 years old;
- Weight\> 3kg;
- Infection with the SARS-CoV-2 virus confirmed by RT-PCR on a upper or low respiratory tract sample or pneumonia with scanner suggesting SARS-CoV-2 infection;
- Hospitalized in a pediatric intensive care unit or in a general pediatrics unit
- Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
- Beneficiary of a social security scheme
- Group E3:
- Age from birth to \<18 years old;
- Weight\> 3 kg;
- Negative SARS-CoV-2 PCR on at least one respiratory sample, and other confirmed viral infection
- Hospitalized in a pediatric intensive care unit or in a general pediatrics unit, for a respiratory reason;
- Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
- Beneficiary of a social security scheme
Exclusion
- Group E1:
- Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
- Other Suspected or proved infection
- Pregnancy.
- Group E2:
- Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
- Pregnancy.
- Group E3:
- Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
- Infection with the SARS-CoV-2 virus known among the relatives
- Pregnancy.
Key Trial Info
Start Date :
May 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 13 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04376476
Start Date
May 5 2020
End Date
May 13 2022
Last Update
April 5 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupement Hospitalier Nord-Daupine
Bourgoin, France, 38300
2
Hôpital femme-mère-enfant
Bron, France, 69677
3
Hôpital Louis Pradel
Bron, France, 69677
4
Hôpital Louis Mourier
Colombes, France, 92700